Chinanews.com, January 29th. According to news from the website of the State Food and Drug Administration on the 29th, recently, the State Food and Drug Administration has conducted emergency review and approval in accordance with the relevant provisions of the "Drug Administration Law" and in accordance with the special approval procedures for drugs, and conditionally approved the first drug in Hainan. Combination packaging of a class 1 innovative drug cenotevir tablets/ritonavir tablets declared by Sheng Pharmaceutical Co., Ltd. (commodity name: senuoxin), a class 1 innovative drug hydrobromic acid declared by Shanghai Wangshi Biomedical Technology Co., Ltd. Deuterium Remidevir Tablets (trade name: Mindevir) are on the market.
Picture from the website of the State Food and Drug Administration
The above two drugs are oral small-molecule novel coronavirus infection treatment drugs for the treatment of adult patients with mild to moderate novel coronavirus infection (COVID-19). Patients should use the medicine strictly according to the instructions under the guidance of doctors
.
The State Food and Drug Administration requires the marketing authorization holder to continue to carry out relevant research work, complete the conditional requirements within a time limit, and submit follow-up research results in a timely manner.
(China New Finance and Economics)